The Latest Cardiac and Vascular News
CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s Zoom System, making it the first comprehensive stroke thrombectomy system to include large-bore .088” catheters indicated for both access and aspiration when used with a Zoom Catheter. This clearance […]
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025.
Revolutionizing care from minimally invasive surgery to comprehensive outpatient services RIYADH, Saudi Arabia, Jan. 27, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its position as a regional leader in advanced cardiac care. Its Heart Centre combines cutting-edge technology with exceptional outcomes, making it the top choice for patients from Saudi Arabia…
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA, Jan. 27, 2025 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic…
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company’s commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.
Two patients at MedStar Union Memorial Hospital receive recently FDA-approved Evoque Tricuspid Valve Replacements for severe tricuspid regurgitation. BALTIMORE, Jan. 24, 2025 /PRNewswire/ — In two separate procedures, MedStar Health cardiac experts at MedStar Union Memorial Hospital…
Niagara Falls, NY, Jan. 24, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical services, is pleased to announce the sale of four and rental of four NeuSight PET-CT 64-slice scanners to a prominent, established provider of advanced diagnostics and treatment for cardiovascular disease. This achievement highlights Positron’s commitment to providing innovative imaging solutions that enable healthcare providers to elevate patient care and achieve superior clinical outcomes.
CrossFAST performance exceeded expectations in ten complex high-risk coronary interventions SAN JOSE, Calif., Jan. 23, 2025 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians with a passion to revolutionize vascular interventions, today…
– U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026- Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology- Multiple non-dilutive opportunities being pursued to fund growth TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) — To our Shareholders, As we…
Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest head-to-head study of a Factor XI inhibitor vs. a direct oral anticoagulant (DOAC) CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) — Anthos Therapeutics, Inc., a transformative, clinical-stage…
